We are creating a new wave of medicines
powered by the human microbiome.
Our Ecobiotic® drugs are a novel approach
to the treatment of disease.
Our lead product candidate received
FDA Breakthrough Therapy designation.
Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases.More
SER-109, our lead development candidate for the prevention of Clostridium difficile infection, has been designated by the FDA as a Breakthrough Therapy.More
The ECOSPORTM Phase 2 clinical study is focused on the safety and efficacy of our Ecobiotic® drug, SER-109, an investigational microbiome therapeutic orally delivered as a capsule.More